Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — Investor Presentation (June 2023)
18 slides from Aethlon Medical's investor presentation, June 2023
Slide 1: Company Overview
Company Overview June 2023 Nasdaq: AEMD www.AethlonMedical.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This investor presentation contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this presentation are forward -looking statements, includin
Slide 3: Investment Highlights
Investment Highlights • Focused on combating cancer and infectious diseases with development of first- in-class immunotherapeutic technologies • Led by seasoned industry executives with extensive development and commercialization experience • Aethlon’s Hemopurifier® has demonstrated the capture of d
Slide 4: Key Financial Highlights
Key Financial Highlights • Approximately $17.5 million in cash as of December 31, 2022 • No debt on balance sheet • Approximately 22.9 million shares outstanding • Market capitalization of $7.2 million, as of May 23, 2023 • Traded on Nasdaq under the ticker AEMD 4
Slide 5: Senior Management Team Has Extensive Experience
Senior Management Team Has Extensive Experience With Both Medical Devices And Therapeutics Companies Charles J. Fisher, Jr., MD, FACP, FCCP, FCCM, Chief Executive Officer • Academic & Industry thought leader in sepsis & inflammation • Head of critical care—Cleveland Clinic • 35 years industry develo
Slide 6: The Aethlon Hemopurifier
The Aethlon Hemopurifier® FDA Designated “Breakthrough Device” In Viral And Oncology Indications • Safely administered in 156 Hemopurifier® sessions in 36 patients • Proprietary, patented mechanism of action • Clears life-threatening viruses • Designed to clear tumor-derived exosomes 6
Slide 7: Mechanism Of Action Captures Virus And Exosomes
The Hemopurifier’s Unique Mechanism Of Action Captures Virus And Exosomes From A Patient’s Blood Via Extracorporeal Circuit Potential Therapeutic Applications: • Cancer • Life-threatening viral infections 7
Slide 8: Pipeline Targeting Multiple Indications
Pipeline Targeting Multiple Indications Early Feasibility Indication Pre-Clinical Pivotal Study Study Cancer Solid Tumors Expected to begin in failing anti- Australia second PD-1 half of 2023 Viral Infection India COVID-19 Ongoing HCV Completed HIV Single patient case study, Completed Emergency Use
Slide 9: Rationale For Removal Of Tumor-Derived Exosomes
Rationale Exists For The Removal Of Tumor-derived Exosomes By Aethlon’s Hemopurifier® To Treat Cancer Exosomes are 50-150nm extracellular vesicles that are released by all cell types, including tumor cells. Specifically, exosomes: • Have been shown to contribute to the spread of cancer (metastases)
Slide 10: In Vitro Removal Of Cancer-Derived Exosomes
In Vitro Removal Of Cancer-derived Exosomes Has Been Demonstrated With A “Benchtop” Hemopurifier® • A scaled down benchtop version of the Hemopurifier® was operated by recirculating samples of cancer patients' plasma through the hollow fiber filters, ex vivo • The exosomes remaining in plasma were q
Slide 11: Clinical Development Plans Underway In Oncology
Clinical Development Plans Underway In Oncology • A new clinical trial in oncology is planned to include more tumor types, as well as dosing intervals to help direct the development of Aethlon’s Hemopurifier® as a treatment option in oncology • The Company has contracted with NAMSA, a major global C
Slide 12: Scientific & Clinical Literature Provide A Rationale
Recent Scientific & Clinical Literature Provide A Rationale For Hemopurifier® Treatment In Severe COVID –19 Infections • COVID viremia is detected in ~34% of patients and is associated with severity, requirement for ICU stay, development of multi-organ failure and poor outcomes • Direct viral injury
Slide 13: Reduction Of Exosomes And Harmful Cargo In COVID-19 Patient
Demonstrated Reduction Of Total Exosomes And Harmful Cargo In An Emergency Use COVID-19 Patient Treated With Hemopurifier® Total Exosomes and Exosomal miRNA over time: miR-424 is associated with COVID-associated miR-16 is associated with acute lung injury coagulopathy (excessive blood clotting) *COV
Slide 14: COVID-19 India Trial Update
COVID-19 India Trial Update: Treatment Of Sars-Cov-2 Infection In Humans With Hemopurifier® Device • Regulatory agency in India has approved the use of Hemopurifier® devices for clinical trial use • Studying ICU patients with severe or life-threatening disease • Designed to include up to 15 patients
Slide 15: Hemopurifier Clinical Development Summary
Hemopurifier® Clinical Development Summary Oncology Viral Infections • Safety, feasibility and dose • Clinical trial of finding study in solid Hemopurifier® in severe tumors failing anti-PD-1 COVID-19 infection antibodies • Currently underway in India • To be initiated first in Australia and then in
Slide 16: Investigating Additional Utility Including Long COVID-19
Investigating Additional Utility Of The Hemopurifier® Including Long COVID-19 • Post-acute Sequelae of COVID-19 infection (PASC) also known as “Long COVID-19” • Materials Transfer Agreement (MTA) in place with University of California San Francisco Medical Center to receive plasma samples in patient
Slide 17: Investment Summary
Investment Summary ▪ Developing novel, patented Hemopurifier® blood purification device ▪ Early trials have demonstrated virus and exosome clearance both in vitro and in patients ▪ Granted two FDA “Breakthrough Device” designations ▪ Focused on multiple therapeutic targets in cancer and viral diseas
Slide 18: Contact Us
Contact Us 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619.941.0360 Nasdaq: AEMD www.AethlonMedical.com This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are s